Medical Access and Reimbursement in New Zealand

Psilocybin sits inside New Zealand's Class A controlled-drug framework. The Matai marae-setting psilocybin pilot is a research and feasibility signal involving healthy volunteers, not a clinical access or reimbursement pathway. # #

MDMA is controlled as Class B1. The visible lawful route is regulated research, including the EMMAC study in advanced-stage cancer, rather than routine psychiatric prescribing or public reimbursement. # #

Spravato is approved in New Zealand and must be administered under healthcare-professional supervision. Current public schedule checks do not support routine funded access, so it should be described as approved but generally unfunded unless a payer or provider confirms otherwise. # #

Ketamine is a Class C controlled medicine and psychiatric use for depression is off-label. Public schedule funding is tied to other settings, while professional guidance and New Zealand commentary frame psychiatric use as specialist and governance-sensitive. # # # #

DMT-related substances should be treated as controlled with no routine medical access route identified in New Zealand. No comparable local clinical-trial pathway was identified for DMT treatment. #

5-MeO-DMT should be treated as controlled or unauthorised for routine care in New Zealand. No approved treatment or reimbursement pathway was identified. # #

No approved or routinely reimbursed ibogaine treatment pathway was identified in New Zealand. Any claimed use would need to fit medicines law, controlled-drug controls and named-patient or research permissions. # #

No authorised ayahuasca medical pathway or reimbursement route was identified in New Zealand. DMT-containing preparations should not be presented as clinically available. # #

Mescaline is covered by New Zealand's Class A controlled-drug framework. No routine medical access or public reimbursement route was identified. #

2C-family compounds should be treated as controlled or unauthorised for medical access purposes. No approved treatment or reimbursement pathway was identified. #